References
- Schusdziarra V, Rouiller D, Harris V, Unger R H. Origin of peripheral venous hypersomatostatinemia in alloxan‐diabetic dogs. Endocrinology 1981; 109: 1107–10
- Hara M, Patton G, Gerich J. Increased somato‐statin release from pancreases of alloxan diabetic rats perfused in vitro. Life Sci 1979; 24: 625–8
- Skare S, Dahl‐JØorgensen K, Hanssen K F, Norman N. Increased peripheral venous somatostatin concentration and decreased glucagon response to arginine in patients with insulin dependent diabetes mellitus without residual B‐cell function. Acta Endocrinol 1985; 109: 517–21
- Wasada T, Howard B, Dobbs R E, Unger R H. Evidence for a role of free fatty acids in the regulation of somatostatin secretion in normal and alloxan diabetic dogs. J Clin Invest 1980; 66: 511–6
- Taborsky G J, Jr, Ensinck J W. Contribution of the pancreas to circulating somatostatin‐like immunoreactivity in the normal dog. J Clin Invest 1983; 73: 216–23
- Skare S, Hanssen K F, Kriz V, Torjesen P A. Arginine infusion increases peripheral plasma somatostatin in man. Clin Endocrinol 1984; 21: 299–308
- Von Schenck H, Nilsson O R. Radioimmunoassay of extracted glucagon compared with 3 non‐extracted assays. Clin Chim Acta 1981; 109: 183–91
- Rutlin E, Haug E, Torjesen P A. Serum thyrotropin, prolactin and growth hormone, response to TRH during oestrogen treatment. Acta Endocrinol 1977; 84: 23–35
- Kawamori R, Schichiri M, Kikuchi M, Yamasaki Y, Abe H. Perfect normalization of excessive glucagon response to intravenous arginine in human diabetes mellitus with the artificial beta‐cell. Diabetes 1980; 29: 762–5